Information  X 
Enter a valid email address

Antisoma Research Limited (SRC)

  Print      Mail a friend       Annual reports

Thursday 04 November, 2004

Antisoma Research Limited

Research Update




Antisoma telomere targeting agent stops tumour growth in prostate
cancer model


London UK, 4 November 2004 - Cancer drug developer Antisoma today
presents new data showing that one of its telomere targeting agents
(TTAs) rapidly blocks prostate tumour growth in a human xenograft
model. While in untreated control animals tumours grew to lethal size
within 10 days, animals given the TTA experienced a halt in tumour
growth at around day 7 and survived to the experiment's end on day
25. These findings extend the range of cancers shown to be
susceptible to Antisoma's TTAs and demonstrate that the drugs have
profound effects on tumour growth even when used as a sole treatment.

The presentation will be given by Antisoma's Head of Research,
Professor Lloyd Kelland, at the AACR Special Conference on The Role
of Telomeres and Telomerase in Cancer in San Francisco. It comes as
the Company, working with the Cancer Research UK Group led by
Professor Stephen Neidle at the London School of Pharmacy, nears
completion of work to select a lead candidate from the TTA programme
for clinical trials.

Professor Kelland commented "What's really exciting about these TTAs
is the speed of their anti-tumour effects. We're not having to wait
for many rounds of cell division before the effects kick in, which
was a major concern with earlier drugs that were pure telomerase
inhibitors."



+-------------------------------------------------------------------+
| Enquiries:                                |                       |
|-------------------------------------------+-----------------------|
|                                           |                       |
|-------------------------------------------+-----------------------|
| Antisoma plc                              |                       |
|-------------------------------------------+-----------------------|
| Daniel Elger, Head of Corporate           | Tel: +44 (0) 7909 915 |
| Communications                            | 068                   |
|-------------------------------------------+-----------------------|
| Office switchboard                        | Tel: +44 (0) 20 8799  |
|                                           | 8200                  |
|-------------------------------------------+-----------------------|
|                                           |                       |
|-------------------------------------------+-----------------------|
| Financial Dynamics                        |                       |
|-------------------------------------------+-----------------------|
| Julia Phillips                            | Tel: +44 (0)20 7831   |
|                                           | 3113                  |
|-------------------------------------------+-----------------------|
|                                           |                       |
|-------------------------------------------+-----------------------|
| De Facto Communications (mainland Europe) |                       |
|-------------------------------------------+-----------------------|
| Richard Anderson                          | Tel: +44 (0)20 7490   |
|                                           | 1000                  |
|-------------------------------------------+-----------------------|
|                                           |                       |
+-------------------------------------------------------------------+



Except for the historical information presented, certain matters
discussed in this statement are forward looking statements that are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from results, performance or
achievements expressed or implied by such statements. These risks and
uncertainties may be associated with product discovery and
development, including statements regarding the company's clinical
development programmes, the expected timing of clinical trials and
regulatory filings. Such statements are based on management's current
expectations, but actual results may differ materially.

Notes for Editors:

About telomere targeting agents (TTAs)
Antisoma has three drugs in clinical trials and three priority
preclinical projects, one of which is the TTA programme. The TTAs
under development at Antisoma were invented by Professor Stephen
Neidle at the Institute of Cancer Research and the London School of
Pharmacy. They were licensed by Antisoma through Cancer Research
Technology, which is part of Cancer Research UK.

Telomeres are protective regions found at the ends of chromosomes
(the structures into which DNA is packaged in each cell of the body).
In normal cells, they shorten slightly with each round of cell
division until they become critically short, causing the cell to
enter the self-destruct programme of apoptosis. Most cancer cells
make the enzyme telomerase, which maintains the length of telomeres
and allows the cells to avoid apoptosis. A number of drugs have been
developed that inhibit telomerase. These are generally characterised
by a slow onset of action because they require rounds of cell
division to 'run down' the telomeres to the point where apoptosis
ensues. TTAs by contrast act more rapidly, binding to the telomere
itself and destabilising it. One clear effect is the uncapping of
chromosome ends leading to lethal end-to-end chromosome fusions. The
action of TTAs is believed to involve prevention of telomerase
binding to the telomere. However, it must have other facets because
the drugs show broad effectiveness against cancer cell lines,
including the minority that use alternative, non-telomerase
mechanisms to maintain their telomeres.

About Antisoma
Based in London, UK, Antisoma is a biopharmaceutical company that
develops novel products for the treatment of cancer. The Company
fills its development pipeline by acquiring promising new product
candidates from internationally recognised academic or cancer
research institutions.  Its core activity is the preclinical and
clinical development of these drug candidates. Antisoma forms
partnerships with pharmaceutical companies to bring its products to
market.  In November 2002, Antisoma formed a broad strategic alliance
with Roche to develop and commercialise products from Antisoma's
pipeline. Please visit www.antisoma.com for further information about
Antisoma.


---END OF MESSAGE---